condition results from direct drug cytotoxicity to the eccrine coils via secretions in the sweat. [3, [6] [7] [8] The other hypothesis classifies NEH as one of the neutrophilic dermatoses. [3, 4, 9, 10] NEH should be differentiated from cellulitis, Sweet syndrome, and leukemia cutis due to its clinical manifestation and patients' characteristics. The correct diagnosis of NEH can prevent the application of unnecessary treatment to NEH patients.
CAsE rEport
The present case involved a 34-year-old female patient who had suffered from uterine adenocarcinoma for 2 years. A staging laparotomy was performed followed by six cycles of chemotherapy with cisplatin and ifosfamide at that time.
However, about 3 months before hospitalization this time, the patient began to experience fever, abdominal pain, and hematuria. Tumor recurrence with invasion to her bladder was found. She then underwent excision of the recurrent pelvic adenosarcoma and started to receive pazopanib 800 mg per day. There was no other concomitant medication.
After 9 weeks of pazopanib therapy, the patient suffered from tender erythematous rashes on the bilateral thighs associated with fever. The initial impression of a gynecologist was cellulitis, so the pazopanib treatment was halted, and the patient was hospitalized for antibiotic therapy. She received oxacillin followed by augmentin, and her treatment was then escalated to teicoplanin and amikacin. Nevertheless, the skin lesions still progressed and her fever persisted after 1 week of antibiotic therapy. Therefore, we visited her at her dermatology consultation. The physical examination revealed multiple well-demarcated, erythematous, edematous, tender plaques with variable diameters of 5-11 cm on the bilateral thighs. The plaques exhibited no epidermal changes [ Figure 1 ]. A skin biopsy was taken from one of the left thigh lesions. The histopathological findings demonstrated mild hyperkeratosis, mild acanthosis, papillary edema, perivascular lymphocytic infiltrate with neutrophils, and focal extravasation of erythrocytes in the dermis. The sweat glands were also infiltrated by lymphocytes and neutrophils, and neutrophils were also seen in the lumens of the sweat glands [ Figure 2 ]. The final diagnosis was NEH. The patient's antibiotic treatment was thus stopped, and she began to receive 8 mg of oral methylprednisolone twice per day. The skin lesions and fever subsided gradually, with only some postinflammatory hyperpigmentation remaining. However, she was then started again on pazopanib therapy after her recovery, and recurrent skin lesions were noted 3 weeks later. Methylprednisolone at 4 mg per day was then given for further treatment. After a subsequent 3-month-long course of pazopanib treatment, she had no recurrent rashes.
disCussion
NEH can be categorized into three main types according to its different etiologies and susceptible groups. The majority of reported cases of NEH have occurred in patients with malignancies, especially patients with AML, who were receiving chemotherapy. [2, 3] A second form of NEH, affecting the palms and soles of healthy children, is also called idiopathic plantar hidradenitis or NEH in children. This type of NEH may be associated with exercise causing heavy sweating or occlusive footwear. Most of the children with this type of NEH experienced spontaneous resolution. [2] Finally, NEH can also result from bacterial infections, such as infections caused by Serratia, Staphylococcus, Enterococcus, Mycobacterium, and Pseudomonas, [11] [12] [13] [14] and these infections may cause community outbreak contamination. [2] Bachmeyer and Aractingi [3] reviewed 51 reported cases of NEH, excluding cases involving the palmoplantar and microorganism-related types. Their analysis of these 51 patients revealed that a slight majority of the patients were male and that their mean age was about 40 years. The clinical manifestation of NEH in these patients was variable, although they most commonly presented with infiltrated erythematous papules or plaques without epidermal changes. These lesions could be painful or asymptomatic. Purpuric changes or the formation of pustules were found in some cases. The diversity in the size, number, and affected body sites of the skin lesions in these cases of NEH made the diagnosis more challenging; however, the pathergy phenomenon and axillary or inguinal area sparing were noted as possible clues. Fever and neutropenia might also occur in NEH patients. [2] As a result, NEH should be carefully differentiated from cellulitis, Sweet syndrome, and leukemia cutis in clinical practice.
Ninety percent of the 51 NEH patients reviewed by Bachmeyer and Aractingi suffered from some form malignancy, most commonly AML. [3] They have reported other hematologic malignancies or solid tumors. With respect to solid tumors, testicular carcinoma was most often reported. However, there were no previous NEH cases involving uterine adenocarcinoma. In the past NEH cases, nearly all the patients had a history of drug administration before the NEH lesions appeared. Most of those medications consisted of antineoplastic therapy, and it is notable that cytarabine and the anthracycline were most commonly implicated. Nonetheless, other medications, such as granulocyte colony-stimulating factor, may also induce NEH. One hypothesis for the pathomechanism of NEH is that it may be due to the direct cytotoxic effects of the drugs on the eccrine glands. Therefore, recurrences may occur when a patient is exposed again to the same therapy. Meanwhile, NEH has been reported as a paraneoplastic syndrome, although that is only true for a few cases. NEH could occur before the onset or relapse of a hematologic malignancy. [15] [16] [17] In the present case, the NEH recurred after the reintroduction of pazopanib treatment for uterine adenocarcinoma. According to the chronological order of the patient's clinical history and the further identification of a probable cause based on the Naranjo scoring criteria, the data for this patient strongly suggested that her NEH was pazopanib induced. [18] Pazopanib, with commercial name of votrient, is a multi-targeted receptor tyrosine kinase inhibitor. It mainly works by inhibiting vascular endothelial growth factor receptor, platelet endothelial growth factor receptor, and stem-cell factor receptor and by blocking tumor growth by inhibiting angiogenesis. [19] The most common side effects of pazopanib are liver dysfunction and hypertension. There have only been a few reports about dermatologic adverse events induced by pazopanib, including hair color changes, hypopigmentation, hand-foot skin reactions, and stomatitis. [19, 20] Previous studies had, however, demonstrated a case of NEH induced by a tyrosine kinase inhibitor. In that case, the only reported case, the patient received 400 mg of oral imatinib mesylate daily. Three months later, progressive erythematous papules were noted on the patient's medial thighs and hands, and the histopathological findings for these papules indicated NEH. The lesions disappeared within 3 weeks after the discontinuation of imatinib. However, the gradual reintroduction of imatinib did not lead to a recurrence of NEH in this case. [21] Although treatment of NEH with colchicine, dapsone, and corticosteroids has shown benefits clinically, most cases of NEH spontaneously resolve within several weeks after discontinuing the culprit medication. [2, 3] Dapsone treatment has, meanwhile, shown the prevention of recurrent NEH in subsequent cycles of the culprit drug. [22] 
ConClusion
We present here a case of NEH following pazopanib use in a patient with uterine adenocarcinoma, wherein the reintroduction of pazopanib induced a recurrence of NEH. To the best of our knowledge, this is the first case of pazopanib-related NEH. Although NEH is rare in patients with uterine adenocarcinoma or undergoing pazopanib treatment, it should be included in the differential diagnosis. The correct diagnosis of NEH can prevent the application of unnecessary treatments to NEH patients.
